MX2009010064A - Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a. - Google Patents

Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a.

Info

Publication number
MX2009010064A
MX2009010064A MX2009010064A MX2009010064A MX2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A
Authority
MX
Mexico
Prior art keywords
methods
specific
signaling
disorders
airway inflammation
Prior art date
Application number
MX2009010064A
Other languages
English (en)
Inventor
Mary Collins
Beatriz M Carreno
Spencer C Liang
Jill F Wright
Frances K Bennett
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009010064A publication Critical patent/MX2009010064A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

La presente invención proporciona un IL-17F/IL-17A de ratón, novedoso, y proporciona además usos de tal IL17F/IL-17A de ratón en la caracterización del heterodírnero de IL-17F/IL-17A. La presente invención también está relacionada con los polinucleótidos y polipéptidos de la ruta de señalización de IL-17F/IL-17A, y ubicar como objetivo la ruta de señalización de IL-17F/IL-17A en los métodos de tratamiento de los trastornos asociados con IL-17F/IL-17A. La invención proporciona así métodos de uso de un heterodirnero de IL-17F/IL-17A aislado, por ejemplo, en un modelo de ratón de la inflamación de las vías respiratorias, y moduladores de IL-17F/IL-17A selectivos o específicos (por ejemplo, los agonistas de señalización o los antagonistas de señalización (por ejemplo, los anticuerpos antagonistas específicos o selectivos, las moléculas pequeñas antagonistas específicas o selectivas, etc.)). La invención también proporciona métodos de selección para los compuestos capaces de modular la actividad biológica de IL-17F/IL-17A, por ejemplo los antagonistas de señalización de IL-17F/IL-17A (por ejemplo, utilizando el modelo de ratón de la inflamación de las vías respiratorias), así como a métodos de identificación de que si el modulador de IL-17F/IL-17A es un modulador de IL-17F/IL-17A específico. La invención también está dirigida a nuevos métodos de diagnóstico, pronóstico, verificación, prevención, y/o tratamiento de los trastornos asociados con IL-17F/IL-17A, incluyendo, pero sin estar limitado a, los trastornos inflamatorios (por ejemplo la artritis (incluyendo la artritis reumatoide), psoriasis, lupus eritematoso sistémico, y esclerosis múltiple), enfermedades respiratorias (por ejemplo, la inflamación de las vías respiratorias, enfermedad pulmonar obstructiva crónica, fibrosis quística, asma, alergia), el rechazo de trasplantes (incluyendo el rechazo de trasplantes de órganos sólidos), y los trastornos o enfermedades inflamatorias del intestino (por ejemplo, colitis ulcerativa, enfermedad de Crohn). La presente invención está dirigida además a nuevas substancias terapéuticas y objetivos terapéuticos identificados por los métodos de selección de la invención, y a los usos de tales substancias terapéuticas en los métodos de tratamiento y prevención de los trastornos asociados con IL-17F/IL-17A.
MX2009010064A 2007-03-28 2008-03-28 Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a. MX2009010064A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92059107P 2007-03-28 2007-03-28
US92217507P 2007-04-05 2007-04-05
PCT/US2008/058735 WO2008121865A1 (en) 2007-03-28 2008-03-28 Methods and compositions for modulating il-17f/il-17a biological activity

Publications (1)

Publication Number Publication Date
MX2009010064A true MX2009010064A (es) 2009-10-12

Family

ID=39639634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010064A MX2009010064A (es) 2007-03-28 2008-03-28 Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a.

Country Status (10)

Country Link
US (1) US20080241130A1 (es)
EP (1) EP2126585A1 (es)
JP (1) JP2010524850A (es)
AR (1) AR066401A1 (es)
CA (1) CA2680701A1 (es)
CL (1) CL2008000883A1 (es)
MX (1) MX2009010064A (es)
PA (1) PA8773801A1 (es)
TW (1) TW200902064A (es)
WO (1) WO2008121865A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007129263A (ru) * 2005-02-14 2009-03-20 Вайет (Us) Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение
CA2752908A1 (en) * 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
AU2010291985B2 (en) * 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011140484A1 (en) * 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
MA34907B1 (fr) 2011-01-14 2014-02-01 Ucb Pharma Sa Molécules d'anticorps se liant à il-17a et il-17f
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN105420237A (zh) * 2015-09-08 2016-03-23 中国农业科学院兰州兽医研究所 靶向抑制小鼠白细胞介素17A基因的序列siRNA-180
WO2017072183A1 (en) * 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5830877A (en) * 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5484909A (en) * 1993-09-10 1996-01-16 Amoco Corporation Nucleic acid probes for the detection of bacteria of the genera Pediococcus and Lactobacillus and methods for the detection of the bacterial agents causing spoilage of beer
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
CA2215394C (en) * 1995-03-23 2011-04-26 Immunex Corporation Il-17 receptor
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6902735B1 (en) * 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
US6635443B1 (en) * 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100835786B1 (ko) * 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
CN101001871A (zh) * 2004-06-10 2007-07-18 津莫吉尼蒂克斯公司 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法
US20060039902A1 (en) * 2004-08-05 2006-02-23 Young Deborah A Antagonizing interleukin-21 receptor activity
RU2007129263A (ru) * 2005-02-14 2009-03-20 Вайет (Us) Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение

Also Published As

Publication number Publication date
PA8773801A1 (es) 2008-11-19
AR066401A1 (es) 2009-08-19
TW200902064A (en) 2009-01-16
CA2680701A1 (en) 2008-10-09
US20080241130A1 (en) 2008-10-02
EP2126585A1 (en) 2009-12-02
JP2010524850A (ja) 2010-07-22
CL2008000883A1 (es) 2008-10-03
WO2008121865A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
MX2009010064A (es) Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a.
TW200641353A (en) Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
HRP20171176T1 (hr) C5ar antagonisti
NZ785586A (en) Novel quinazolinones and related compounds for use as anti-inflammatory agents
EA201200876A1 (ru) Новые антагонисты рецептора ccr2 и их применение
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
PH12015501713B1 (en) Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
NO20074961L (no) Imidazopyridazinforbindelser
WO2007102883A3 (en) Chemical compounds
WO2008071605A3 (en) Methods of treating inflammatory diseases
Kumar et al. Diversity of vascular niches in bones and joints during homeostasis, ageing, and diseases
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2008060814A3 (en) ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2007035823A3 (en) Partial mglur5 antagonists and methods of use thereof
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2009151518A3 (en) Methods and compositions for predicting development of atopic diseases
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2010065546A3 (en) MAINTENANCE/EXPANSION OF HSCs
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
Thompson et al. Puberty-Associated Dna Methylation Changes In Females Are Near Estrogen Responsive Genes And Implicated In Immune Processes
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
Sadeghi et al. The Effects of Deferoxamine on the Up regulation of Chemokine Receptor 2 in Bone Marrow Stromal Stem Cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal